Piper Sandler on Amgen (AMGN): 'We Envision a Path to Multiple Expansion'

January 17, 2025 10:48 AM EST Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $310.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login